Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference

Our Bureau

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will participate at the 2023 Cantor Global Healthcare Conference, taking place September 26-28, 2023, in New York, NY.

Todd Harris, CEO of TYRA, will participate in a fireside chat on Wednesday, September 27, 2023, at 10:20 am ET.

A live and archived webcast of the fireside chat will be available via the For Investors page on the Investor section of the TYRA website.


Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

Fluent BioSciences Awarded NIH SBIR Grant to Revolutionize Single Cell Analysis

Fluent BioSciences, a cutting edge life sciences company leading the charge in revolutionizing single cell analysis through simple, cost-effective, and highly scalable single-cell RNA sequencing solutions is thrilled to announce the award of an NIH Small Business Innovation Research (SBIR) Phase II grant, funded by the National Institute of General […]
Fluent BioSciences NIH SBIR Phase II Grant

Subscribe Now